Kathryn Mileham, MD
Medical Oncology · Charlotte, NCNPI 1568519411
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $76,657 of the $110,356 with a category attached, or 69.5%. 15 manufacturers reported payments, led by AstraZeneca at 34.6% of the total. Reporting peaked in 2019 at $28,517 and has fallen 63.4% since, to $10,450 in 2025. Among medical oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $1254.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$38K
- Merck$36K
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- Lilly USA, LLC$6K
- Blueprint Medicines Corporation$5K
- Regeneron Healthcare Solutions, Inc.$4K
- plus $10K from 9 others
Across 330 payments — averaging $14,034 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.7M
- Merck$1.7M
- Bayer$72K
- Eli Lilly$59K
- Takeda Pharmaceuticals U.S.A., Inc.$52K
- Boehringer Ingelheim International GmbH$36K
- plus $38K from 3 others
What the payments were for
- Consulting fees$76,65769%
- Speaking & faculty fees$26,15624%
- Travel & lodging$6,0996%
- Food & beverage$1,3641%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $38,155 |
| Merck | 31 | $35,780 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $11,175 |
| Lilly USA, LLC | 2 | $5,714 |
| Blueprint Medicines Corporation | 2 | $5,141 |
| Regeneron Healthcare Solutions, Inc. | 4 | $4,061 |
| AbbVie | 1 | $2,900 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,970 |
| Johnson & Johnson | 2 | $1,810 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Bayer | 1 | $1,428 |
| Genentech USA, Inc. | 1 | $550 |
| Amgen | 1 | $65 |
| Jazz Pharmaceuticals Inc. | 1 | $62 |
| Janssen Scientific Affairs, LLC | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$110,356 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 22 | $464 |
| Mirtazapine | 15 | $277 |
| Prochlorperazine Maleate | 29 | $233 |
| Ondansetron Hcl | 25 | $173 |
| Prednisone | 25 | $58 |
| Furosemide | 13 | $23 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charlotte
- David RizzieriCharlotte$714K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Edward KimCharlotte$188K
- Antoinette TanCharlotte$89K
- Jimmy HwangCharlotte$64K
- Ashley SumrallCharlotte$55K
- Obiageli OgbataCharlotte$26K
- Daniel CarrizosaCharlotte$20K
- Daniel HaggstromCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.